{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T07:10:17Z","timestamp":1729321817449,"version":"3.27.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.eimce.2023.04.015","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T12:17:58Z","timestamp":1682511478000},"page":"236-241","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elimination of hepatitis C virus in a prison: An 18-year experience"],"prefix":"10.1016","volume":"42","author":[{"given":"Maite","family":"Nogales-Garcia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naiara","family":"Parraza Diez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andoni","family":"Vargas Axpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Velasco Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ane","family":"Larrabeiti-Etxebarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Roy Lopez-Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Atrio Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asier","family":"Lopez de Arcaute Trincado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva Mar\u00eda","family":"Fernandez Lopez de Vicu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Saez de Adana Arroniz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Mart\u00ednez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseba","family":"Portu Zapirain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eimce.2023.04.015_bib0005","unstructured":"World Health Organization. Hepatitis C [Internet]. 2019 [accessed 9 Jan 2022]. Available from: https:\/\/www.who.int\/es\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"10.1016\/j.eimce.2023.04.015_bib0010","unstructured":"Grupo de trabajo del estudio de prevalencia de la infecci\u00f3n por hepatitis C en poblaci\u00f3n general en Espa\u00f1a; 2017-2018. Resultados del 2.\u00ba estudio de seroprevalencia en Espa\u00f1a (2017-2018). Ministerio de Sanidad, Consumo y Bienestar Social; 2019."},{"key":"10.1016\/j.eimce.2023.04.015_bib0015","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/hep.26387","article-title":"Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis","volume":"58","author":"Larney","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.eimce.2023.04.015_bib0020","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.4254\/wjh.v7.i21.2323","article-title":"Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment","volume":"7","author":"Zampino","year":"2015","journal-title":"World J Hepatol."},{"key":"10.1016\/j.eimce.2023.04.015_bib0025","unstructured":"Secretar\u00eda General de Instituciones Penitenciarias. Subdirecci\u00f3n General de Coordinaci\u00f3n de Sanidad Penitenciaria. Prevalencia de las infecciones VIH y VHC en Instituciones Penitenciarias. A\u00f1o 2018. [Internet]. 2018 [accessed 9 Jan 2022]. Available from: http:\/\/www.institucionpenitenciaria.es\/web\/export\/sites\/default\/datos\/descargables\/saludpublica\/Prevalencia_VIH_y_VHC_en_IIPP_2018.pdf."},{"issue":"Espec Cong 2","key":"10.1016\/j.eimce.2023.04.015_bib0030","first-page":"36","article-title":"III Congreso Nacional del Grupo de Estudio de las Hepatitis V\u00edricas (GEHEP) de la SEIMC. P-079. Evoluci\u00f3n del virus de la hepatitis C en pacientes institucionalizados en un centro penitenciario","volume":"35","author":"Nogales Garcia","year":"2017","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.eimce.2023.04.015_bib0035","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090560","article-title":"Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period","volume":"9","author":"Marco","year":"2014","journal-title":"PLoS ONE."},{"key":"10.1016\/j.eimce.2023.04.015_bib0045","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12889-018-6357-x","article-title":"Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and Practice Assessment in Europe","volume":"19","author":"St\u00f6ver","year":"2019","journal-title":"BMC Public Health."},{"key":"10.1016\/j.eimce.2023.04.015_bib0050","unstructured":"European Centre for Disease Prevention and Control. Public health guidance on prevention and control of blood-borne viruses in prison settings: prevention and control of communicable diseases in prison settings. [Internet]. 2018 [accessed 27 Nov 2022]. Available from: https:\/\/data.europa.eu\/doi\/10.2900\/042079."},{"key":"10.1016\/j.eimce.2023.04.015_bib0055","unstructured":"World Health Organization. Access to hepatitis C testing and treatment for people who inject drugs and people in prisons: A global perspective: Policy brief, April 2019 [Internet]. World Health Organization; 2019 [accessed 27 Nov 2022]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/312116."},{"key":"10.1016\/j.eimce.2023.04.015_bib0060","unstructured":"World Health Organization. Estrategia Mundial del sector de la salud contra las hepatitis v\u00cdricas 2016-2021: Hacia el fin de las hepatitis v\u00edricas [Internet]. World Health Organization; 2016 [accessed 9 Jan 2022]. Available from: https:\/\/apps.who.int\/iris\/handle\/10665\/250578."},{"key":"10.1016\/j.eimce.2023.04.015_bib0065","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination \u2013 a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J Hepatol."},{"key":"10.1016\/j.eimce.2023.04.015_bib0070","unstructured":"Secretar\u00eda General de Sanidad y Consumo. Ministerio de Sanidad, Consumo y Bienestar Social. Plan Estrat\u00e9gico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud (PEAHC) [Internet]. Ministerio de Sanidad, Consumo y Bienestar Social. 2018 [accessed 9 Jan 2022]. Available from: https:\/\/www.mscbs.gob.es\/ciudadanos\/enfLesiones\/enfTransmisibles\/hepatitisC\/PlanEstrategicoHEPATITISC\/docs\/Plan_Estrategico_Abordaje_Hepatitis_C_(PEAHC).pdf."},{"key":"10.1016\/j.eimce.2023.04.015_bib0075","unstructured":"Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults [Internet]. Centers for Disease Control and Prevention. 1992 [accessed 27 Nov 2022]. Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/00018871.htm."},{"key":"10.1016\/j.eimce.2023.04.015_bib0080","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.eimce.2023.04.015_bib0085","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0090","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1053\/jhep.2002.36812","article-title":"Treatment of patients with hepatitis C and cirrhosis","volume":"36","author":"Wright","year":"2002","journal-title":"Hepatology."},{"key":"10.1016\/j.eimce.2023.04.015_bib0095","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0100","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0105","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1009482","article-title":"Boceprevir for previously treated chronic HCV genotype 1 infection","volume":"364","author":"Bacon","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0110","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","article-title":"Telaprevir for retreatment of HCV infection","volume":"364","author":"Zeuzem","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.eimce.2023.04.015_bib0115","unstructured":"Departamento de Medicamentos de Uso Humano. Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de posicionamiento terap\u00e9utico de glecaprevir\/pibrentasvir. IPT, 8\/2018. V1. [Internet]. [accessed 9 Jan 2022]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-glecaprevir-pibrentasvir-Maviret-hepatitisC.pdf."},{"key":"10.1016\/j.eimce.2023.04.015_bib0120","unstructured":"Departamento de Medicamentos de Uso Humano. Agencia Espa\u00f1ola del Medicamento y Productos Sanitarios. Ministerio de Sanidad, Servicios Sociales e Igualdad. Informe de Posicionamiento Terap\u00e9utico de sofosbuvir\/velpatasvir en hepatitis C. IPT, 19\/2017. V1. [Internet] [accessed 9 Jan 2022]. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-sofosbuvir-velpatasvir-Epclusa-hepatitisC.pdf."},{"key":"10.1016\/j.eimce.2023.04.015_bib0125","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4321\/S1575-06202019000100006","article-title":"Is it possible to eliminate hepatitis C from the prisons of Catalonia, Spain, in 2021?","volume":"21","author":"Marco","year":"2019","journal-title":"Rev Esp Sanid Penit."},{"key":"10.1016\/j.eimce.2023.04.015_bib0130","first-page":"88","article-title":"Interrupci\u00f3n del tratamiento de la hepatitis C cr\u00f3nica con antivirales de acci\u00f3n directa por causas de origen penitenciario en las prisiones de Catalu\u00f1a","volume":"S18","author":"Marco Mourino","year":"2016","journal-title":"Rev Esp Sanid Penit."},{"key":"10.1016\/j.eimce.2023.04.015_bib0135","first-page":"87","article-title":"Eficacia, seguridad y discontinuaci\u00f3n del tratamiento de la Hepatitis C Cr\u00f3nica con antivirales de acci\u00f3n directa en las prisiones de Catalu\u00f1a","volume":"S18","author":"Touz\u00f3n-L\u00f3pez","year":"2016","journal-title":"Rev Esp Sanid Penit."},{"key":"10.1016\/j.eimce.2023.04.015_bib0140","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/MEG.0000000000000163","article-title":"Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study)","volume":"26","author":"De Juan","year":"2014","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.eimce.2023.04.015_bib0145","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/jvh.12998","article-title":"A systematic review on models of care effectiveness and barriers to hepatitis C treatment in prison settings in the EU\/EEA","volume":"25","author":"Vroling","year":"2018","journal-title":"J Viral Hepat."},{"key":"10.1016\/j.eimce.2023.04.015_bib0150","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/jvh.12940","article-title":"Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates","volume":"25","author":"Marco","year":"2018","journal-title":"J Viral Hepat."}],"container-title":["Enfermedades infecciosas y microbiologia clinica (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X23001284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2529993X23001284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T06:54:31Z","timestamp":1729320871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2529993X23001284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2529993X23001284"],"URL":"https:\/\/doi.org\/10.1016\/j.eimce.2023.04.015","relation":{},"ISSN":["2529-993X"],"issn-type":[{"type":"print","value":"2529-993X"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elimination of hepatitis C virus in a prison: An 18-year experience","name":"articletitle","label":"Article Title"},{"value":"Enfermedades infecciosas y microbiologia clinica (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eimce.2023.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.eimc.2023.01.002","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}